Difference between revisions of "Nintedanib (Vargatef)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "http://ascopubs.org" to "https://ascopubs.org") |
m |
||
| Line 1: | Line 1: | ||
| − | =Mechanism of action= | + | ==Mechanism of action== |
From the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=504524 NCI Drug Dictionary]: An orally bioavailable, indolinone-derived, receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities. Multitargeted tyrosine kinase inhibitor BIBF 1120 selectively binds to and inhibits vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR) and platelet-derived growth factor receptor (PDGFR) tyrosine kinases, which may result in the induction of endothelial cell apoptosis; a reduction in tumor vasculature; and the inhibition of tumor cell proliferation and migration. In addition, this agent also inhibits members of the Src family of tyrosine kinases, including Src, Lck, Lyn, and FLT-3 (fms-like tyrosine kinase 3). | From the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=504524 NCI Drug Dictionary]: An orally bioavailable, indolinone-derived, receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities. Multitargeted tyrosine kinase inhibitor BIBF 1120 selectively binds to and inhibits vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR) and platelet-derived growth factor receptor (PDGFR) tyrosine kinases, which may result in the induction of endothelial cell apoptosis; a reduction in tumor vasculature; and the inhibition of tumor cell proliferation and migration. In addition, this agent also inhibits members of the Src family of tyrosine kinases, including Src, Lck, Lyn, and FLT-3 (fms-like tyrosine kinase 3). | ||
| − | = | + | ==Diseases for which it is used== |
| − | ==[[Mesothelioma]] | + | *[[Mesothelioma]] |
| − | * | + | *[[Non-small cell lung cancer]] |
| + | *[[Ovarian cancer]] | ||
| − | == | + | ==History of changes in FDA indication== |
| − | + | ''Not FDA approved at this time.'' | |
| − | |||
| − | == | + | ==Also known as== |
| − | * ''' | + | *'''Code name:''' BIBF 1120 |
| + | *'''Brand names:''' Ofev, Vargatef | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
| Line 22: | Line 23: | ||
[[Category:SRC inhibitors]] | [[Category:SRC inhibitors]] | ||
| − | [[Category: | + | [[Category:Mesothelioma medications]] |
| + | [[Category:Non-small cell lung cancer medications]] | ||
| + | [[Category:Ovarian cancer medications]] | ||
| + | |||
| + | [[Category:EMA approved drugs]] | ||
Revision as of 20:27, 6 September 2019
Mechanism of action
From the NCI Drug Dictionary: An orally bioavailable, indolinone-derived, receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities. Multitargeted tyrosine kinase inhibitor BIBF 1120 selectively binds to and inhibits vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR) and platelet-derived growth factor receptor (PDGFR) tyrosine kinases, which may result in the induction of endothelial cell apoptosis; a reduction in tumor vasculature; and the inhibition of tumor cell proliferation and migration. In addition, this agent also inhibits members of the Src family of tyrosine kinases, including Src, Lck, Lyn, and FLT-3 (fms-like tyrosine kinase 3).
Diseases for which it is used
History of changes in FDA indication
Not FDA approved at this time.
Also known as
- Code name: BIBF 1120
- Brand names: Ofev, Vargatef